Histology
Non-Small Cell Carcinoma
CI-CAN-00001292Explore in graph →
1,752 active trials47 approved drugs589 evidence items
- NCIt
- C65151
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00001292Explore in graph →
Clinical trials
6,757 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,046)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer(RATIONALE001) | terminated | Phase 3 | 1 | CelgeneINDUSTRY | 23 | Jul 15, 2020 | clinicaltrials |
| NCT00840749 | Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer(STARS) | terminated | N/A | 36 | Accuray IncorporatedINDUSTRY |
| 4 |
| Jul 14, 2020 |
| clinicaltrials |
| NCT02193152 | Pazopanib in Molecularly Selected Patients With Advanced NSCLC | terminated | Phase 2 | 16 | Washington University School of MedicineOTHER | 1 | Jul 14, 2020 | clinicaltrials |
| NCT01857271 | Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer(EVENT) | terminated | Phase 2 | 3 | Albert Einstein College of MedicineOTHER | 1 | Jul 8, 2020 | clinicaltrials |
| NCT02387125 | Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1 | terminated | Phase 1 | 79 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 1, 2020 | clinicaltrials |
| NCT02004184 | Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy(IDA) | terminated | Phase 3 | 230 | Norwegian University of Science and TechnologyOTHER | 1 | Jun 23, 2020 | clinicaltrials |
| NCT03343613 | A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | terminated | Phase 1 | 60 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 9, 2020 | clinicaltrials |
| NCT03411473 | Study of AGEN1884 With Pembrolizumab in 1L NSCLC | terminated | Phase 2 | 2 | Agenus Inc.INDUSTRY | 2 | Jun 2, 2020 | clinicaltrials |
| NCT00420732 | Vaccine Maintenance Treatment for Non-Small Cell Lung Cancer | terminated | Phase 2 | 6 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01774578 | Immunotherapy Study in Progressive or Relapsed Non-Small Cell Lung Cancer | terminated | Phase 2 / Phase 3 | 135 | NewLink Genetics CorporationINDUSTRY | 1 | May 28, 2020 | clinicaltrials |
| NCT01809756 | The Effect of Caphosol® on the Development of Esophagitis in (N)SCLC Patients Treated With Concurrent Chemo/Radiotherapy(CARACTER) | terminated | N/A | 55 | Amphia HospitalOTHER | 1 | Apr 7, 2020 | clinicaltrials |
| NCT02452463 | Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy | terminated | Phase 2 | 8 | Roswell Park Cancer InstituteOTHER | 1 | Apr 6, 2020 | clinicaltrials |
| NCT02926638 | Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches | terminated | Phase 2 / Phase 3 | 9 | SWOG Cancer Research NetworkNETWORK | 1 | Mar 19, 2020 | clinicaltrials |
| NCT03574818 | Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001 | terminated | Phase 2 | 1 | Montefiore Medical CenterOTHER | 1 | Mar 18, 2020 | clinicaltrials |
| NCT01110226 | Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies(0805GCC) | terminated | Phase 1 | 23 | University of Maryland, BaltimoreOTHER | 1 | Mar 17, 2020 | clinicaltrials |
| NCT03580694 | Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 17 | Regeneron PharmaceuticalsINDUSTRY | 1 | Mar 13, 2020 | clinicaltrials |
| NCT01717482 | Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer | terminated | Phase 2 | 6 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT03198117 | Huaier Granule for Prevention of Recurrence and Metastasis of Stage II and III Non-small Cell Lung Cancer (NSCLC) | terminated | N/A | 6 | Qidong Gaitianli Medicines Co., LtdINDUSTRY | 1 | Mar 9, 2020 | clinicaltrials |
| NCT02452424 | A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | terminated | Phase 1 / Phase 2 | 78 | Daiichi SankyoINDUSTRY | 1 | Mar 5, 2020 | clinicaltrials |
| NCT03460678 | Randomized Comparative Study of Erlotinib and Pemetrexed in the Maintenance Treatment of Advanced Lung Cancer Patients. | terminated | Phase 4 | 9 | Hikma Pharmaceuticals LLCINDUSTRY | 2 | Mar 5, 2020 | clinicaltrials |
| NCT02468661 | A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification | terminated | Phase 1 | 23 | Novartis PharmaceuticalsINDUSTRY | 10 | Feb 24, 2020 | clinicaltrials |
| NCT02134912 | S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 20, 2020 | clinicaltrials |
| NCT02469701 | Advanced Non-Small Cell Lung Cancer Progressing After at Least One Prior Therapy For Metastatic Disease | terminated | Phase 2 | 10 | howard safranOTHER | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01392352 | HYPAZ: Hypertension Induced by Pazopanib(HYPAZ) | terminated | Phase 2 | 31 | Cambridge University Hospitals NHS Foundation TrustOTHER | 1 | Feb 13, 2020 | clinicaltrials |
| NCT02576665 | A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6) | terminated | Phase 1 | 21 | Tocagen Inc.INDUSTRY | 1 | Feb 7, 2020 | clinicaltrials |
| NCT02117024 | A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer | terminated | Phase 2 | 66 | Heat BiologicsINDUSTRY | 1 | Feb 5, 2020 | clinicaltrials |
| NCT01707823 | Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer | terminated | Early Phase 1 | 4 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jan 14, 2020 | clinicaltrials |
| NCT01574300 | Collaborative Advanced Stage Tissue Lung Cancer (CASTLE) Network(CASTLE) | terminated | — | 136 | Addario Lung Cancer Medical InstituteOTHER | 0 | Jan 10, 2020 | clinicaltrials |
| NCT01165658 | Study of Hypofractionated Proton Radiation Therapy in Thoracic Malignancies | terminated | Phase 1 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 2, 2020 | clinicaltrials |
| NCT01918761 | Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | terminated | Phase 1 | 5 | Central European Cooperative Oncology GroupOTHER | 1 | Dec 30, 2019 | clinicaltrials |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body | terminated | Phase 1 | 51 | Eli Lilly and CompanyINDUSTRY | 4 | Dec 27, 2019 | clinicaltrials |
| NCT03564054 | Trial of Photodynamic Therapy Versus Argon Plasma Coagulation for Lung Cancer With Endobronchial Obstruction | terminated | N/A | 3 | University of FloridaOTHER | 1 | Dec 18, 2019 | clinicaltrials |
| NCT01413451 | Amatuximab for High Mesothelin Cancers | terminated | Early Phase 1 | 7 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT01441128 | -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 17, 2019 | clinicaltrials |
| NCT00094978 | Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum | terminated | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Dec 12, 2019 | clinicaltrials |
| NCT02501707 | Echocardiography for RILI Prediction | terminated | — | 15 | Maastricht Radiation OncologyOTHER | 1 | Dec 4, 2019 | clinicaltrials |
| NCT03232892 | Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer | terminated | Phase 2 | 1 | University of California, San FranciscoOTHER | 1 | Dec 3, 2019 | clinicaltrials |
| NCT00923273 | Sirolimus and Pemetrexed to Treat Non-Small Cell Lung Cancer | terminated | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Nov 26, 2019 | clinicaltrials |
| NCT02770014 | Rapid Plasma Genotyping For Early Initiation Of Erlotinib In EGFR Mutant Lung Cancer | terminated | Phase 2 | 43 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 22, 2019 | clinicaltrials |
| NCT03272971 | Feasibility Study of the RF Ablation Catheter to Ablate Lung Tumors | terminated | N/A | 3 | Broncus Medical IncINDUSTRY | 1 | Nov 1, 2019 | clinicaltrials |
| NCT02448251 | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer | terminated | Phase 1 | 28 | ACEA Therapeutics, Inc.INDUSTRY | 3 | Oct 29, 2019 | clinicaltrials |
| NCT02920450 | Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) | terminated | Phase 1 / Phase 2 | 3 | University of FloridaOTHER | 1 | Oct 4, 2019 | clinicaltrials |
| NCT02062632 | Doxepin Hydrochloride in Treating Esophageal Pain in Patients With Thoracic Cancer Receiving Radiation Therapy to the Thorax With or Without Chemotherapy | terminated | Phase 2 | 5 | Mayo ClinicOTHER | 1 | Oct 1, 2019 | clinicaltrials |
| NCT02002052 | Functional Lung Avoidance for Individualized Radiotherapy (FLAIR): A Randomized, Double-Blind Clinical Trial(FLAIR) | terminated | Phase 2 | 29 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Sep 25, 2019 | clinicaltrials |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | terminated | Phase 1 | 65 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 19, 2019 | clinicaltrials |
| NCT02187367 | Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC Patients(EGF) | terminated | Phase 3 | 106 | Bioven EuropeINDUSTRY | 11 | Sep 10, 2019 | clinicaltrials |
| NCT02937402 | Bronchoscopy With Bronchoalveolar Lavage in Identifying Biomarkers of Response to Immune Checkpoint Inhibitors in Patients With Non-small Cell or Small Cell Lung Cancer | terminated | N/A | 9 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT02132884 | Genetic Sequencing-Informed Targeted Therapy in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer | terminated | N/A | 1 | Fox Chase Cancer CenterOTHER | 1 | Sep 4, 2019 | clinicaltrials |
| NCT03479294 | Real-World Study on Adjuvant Therapy Combined With Shenlingcao Oral Liquid in Patients for Stage II and IIIA Non-small Cell Lung Cancer After Radical Resection | terminated | — | 9 | West China HospitalOTHER | 1 | Aug 26, 2019 | clinicaltrials |
| NCT02054819 | Treating NSCLC Minimal Stage IV With Curative Intent | terminated | Phase 2 | 14 | Leo W. Jenkins Cancer CenterOTHER | 1 | Aug 21, 2019 | clinicaltrials |
Data updated 23 days agoSource updated Jul 15, 2020source: clinicaltrials